CSI Market
Sign In | Register

Acceleron Pharma inc (XLRN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access XLRN Annual Cash Flow →
This cash flow overview for Acceleron Pharma inc spans from Sep 30 2020 to Sep 30 2021, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2021)
9 Months 		(Jun 30 2021) (Mar 31 2021) (Dec 31 2020) (Sep 30 2020)
Operating Activities
Income-197.46
Depreciation & amortization3.22
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation40.53
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Gain Loss On Retirement Of Warrants-
Increase Decrease Operating Lease Liability-5.13
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Due from Related Parties, Current, Total-8.09
Increase (Decrease) in Accounts Payable-3.42
Increase (Decrease) in Accrued Liabilities-0.80
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-54.60
Other Working Capital0.00
Other Noncash Income (Expense)-2.33
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.85
Discontinued operations0.00
Net Cash flow from Operating Activities-223.23
Investing Activities
Capital Expenditures-4.30
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities280.32
Payments to Acquire Marketable Securities-407.58
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-131.56
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Stock Options And Warrants Exercised-
Payments for Capital Lease Expenditures-
Net Proceeds From Stock Options Stock Awards Employee Stock Purchase Plan And Warrants Exercised20.09
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities20.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-227.53
Total Cash Flow-334.70
4 historic quarters locked

Sign in to unlock the full Acceleron Pharma inc cash flow history.

Sign In Create Free Account

About XLRN Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.